|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of NLRC5 in progression and reversal of hepatic fibrosis.
|
26806094 |
2016 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project.
|
21347282 |
2011 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In this study, human clinical data from The Cancer Genome Atlas database revealed that increased NLRC5 expression was associated with advanced stage and poor prognosis in ccRCC patients.
|
30543814 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In this study, human clinical data from The Cancer Genome Atlas database revealed that increased NLRC5 expression was associated with advanced stage and poor prognosis in ccRCC patients.
|
30543814 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Given the importance of CD8<sup>+</sup> T and NK cells in controlling infection and cancer, it is not surprising that NLRC5 is also starting to emerge as a central player in these diseases.
|
28215281 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells.
|
30706093 |
2019 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
To investigate the role of NLRC5 in the activation and reversion of HSCs induced with transforming growth factor-β (TGF-β) and MDI, and to explore its relationship with liver fibrosis.
|
31293340 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mutations affecting the HLA class I transactivator NLRC5 were observed as a potential new immune evasion mechanism in 26% (6% abrogating) of the analyzed tumors.
|
29900056 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
NLRC5 expression was significantly related to lymph nodes and tumor node metastasis (TNM) staging (χ<sup>2</sup>=6.295; χ<sup>2</sup>=6.268).
|
30426081 |
2018 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
As the largest member of the nucleotide‑binding domain and leucine‑rich repeat (NLR) family, NLRC5 has been shown to be pivotal in the development of hepatic fibrosis.
|
28713900 |
2017 |